CARDIOL THERAPEUTICS INC. (CRDL)
Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program
Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program
📈 **POSITIVE** • Medium confidence analysis (70%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business